AI model predicts which breast cancers vanish after chemo
NCT ID NCT07426653
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at data from 298 breast cancer patients to build a computer model that predicts whether chemotherapy before surgery will completely eliminate the cancer. The model uses routine clinical and lab information to estimate the chance of a complete response. It is not a new treatment but a tool to help doctors and patients make better decisions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this model could help doctors predict which breast cancer patients will have a complete response to chemotherapy before surgery, allowing more personalized treatment plans.
- What could go wrong
- This is a retrospective observational study, not a clinical trial testing a new treatment. The model needs further validation in real-world settings before it can be used in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
298 people
The number who actually took part.
- Started
-
Jan 2010
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population consists of patients with breast cancer treated with neoadjuvant chemotherapy at a single tertiary breast care center between January 2010 and December 2025. The registry includes demographic, tumor staging, biomarker, and treatment-related clinicopathological data collected as part of routine clinical care. All patients underwent surgery following neoadjuvant chemotherapy with documented pathological response assessment.
- Ages
-
18 to 90 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically confirmed breast cancer * Receipt of neoadjuvant chemotherapy * Available clinicopathological data required for model development * Surgical treatment performed following neoadjuvant chemotherapy * Pathological response assessment available * Recorded pathological details Exclusion Criteria: * Missing pathological response information * Incomplete clinicopathological data required for model analysis * Patients not treated with neoadjuvant chemotherapy * Non-invasive breast cancer without indication for neoadjuvant treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Can time with horses help cancer patients feel better?
- Can an oral drug replace injections for advanced breast cancer?
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?